SUPN Supernus Pharmaceuticals, Inc.
$40.96▲ +0.47%
Healthcare
Other
After hours
$40.96▲ +0.00%
Oct 27, 4:00 PM ET
Volume 1.08M
Avg Volume (10D) 1.13M
Key Metrics & Fundamentals
Market Cap
$2.38B
P/E Ratio
–
Div Yield
0.00%
52W Range
37.54 - 59.68
% vs 50 MA
-4.53%
% vs 200 MA
-13.65%
RSI-14
45.8
MACD Histogram
+0.0700
Beta (1Y vs SPY)
0.52
Free Cash Flow
-$5.38M
Gross Rev
$219.06M
Gross Profit
$185.39M
EBITDA
$25.33M
COGS
$33.67M
Operating Exp
$188.43M
Operating Income
-$3.04M
EBIT
-$3.04M
Pretax Income
-$57.65M
Net Income
-$58.37M
EPS (Diluted)
-1.01
Price & Volume History
Loading chart…
Recent News
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Zacks · Oct 26, 2026 8:38 AM ET
Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own
Simply Wall St. · Oct 23, 2026 10:09 PM ET
MSG Rangers, Huron Consulting Group to Join S&P SmallCap 600
MT Newswires · Oct 23, 2026 5:51 AM ET
Huron Consulting stock rises on S&P SmallCap 600 addition
Investing.com · Oct 22, 2026 6:27 PM ET
MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600
PR Newswire · Oct 22, 2026 6:08 PM ET
Huron Consulting to Join S&P SmallCap 600
MT Newswires · Oct 22, 2026 5:35 PM ET
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Zacks · Oct 22, 2026 9:00 AM ET
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
GlobeNewswire · Oct 21, 2026 7:45 PM ET
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
GlobeNewswire · Oct 19, 2026 8:30 AM ET
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
StockStory · Oct 14, 2026 5:22 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SUPN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.